Tenon Medical (TNON) said late Monday the US Food and Drug Administration has cleared an expanded indication for its Catamaran SI Joint Fusion System for use in augmenting thoracolumbar fusion.

The Catamaran is now indicated to treat the sacroiliac joint as a stand-alone treatment or to augment a spinal fusion, Tenon said.

The shares were rising over 40% in recent after-hours activity.